http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 서홍석(Hong Seog Seo) (검색결과 35 건)
- 무료
- 기관 내 무료
- 유료
-
한국인의 혈중 Lipoprotein ( a ) 농도와 Apolipoprotein ( a ) 유전적 표현형 분포특성
서홍석(Hong Seog Seo),오동주(Dong Joo Oh),이상칠(Sang Chil Lee),임도선(Do Sun Lim),박창규(Chang Kyu Park),김영훈(Young Hoon Kim),심완주(Wan Joo Shim),노영무(Young Moo Ro),김순덕(Soon Duk Kim),유재명(Jae Myung Yu) 대한내과학회 1996 대한내과학회지 Vol.50 No.5
N/A Lipoprotein(a)[Lp(a)] is a cholestryl ester-rich lipoprotein composed of two components' an LDL -like particle to which is attached a single large glycoprotein, apolipoprotein(a)[apo(a)]. Elevated concentrations of Lp(a) have been established as a geneticalqly controlled risk factor for atherosclerotic vascular disease. Variable alleles at the apo(a) gene locus determine, to a large extent, the Lp(a) concentration in the general population. To determine and compare the mean and distribution of Lp(a) concentration, apo(a) phenotypes and allele frequencies of Lp(a) in Korean people and other several esthnic groups, we investigated the Lp(a) plasma concentration, apo(a) phenotypes and other lipid profiles in 481 Korean People, who were consisted of 280 cases with non-atherosclerotic vascular disease and 201rases with atherosclerotic vascular disease. Mean concentrations of Lp(a) in Korean people were 27.3±28.6mg/dl in cases with non-atherosclerotic vascular disease an 29.9±31.2mg/dl in cases with atherocslerotic vascular disease. No differences was found in Lp(a) doncentration between the two groups. Lp(a) concentration of Korean people was simular to those of Indian, but far higher than those of Caucacian, Chinese or Japanese. Proportion of those below 5mg/dl of Lp(a) concentration was 26.6%, and those below 30mg/ dl was 68.0%. Frequency distribution patterns of Lp(a) concentrations in Korean population were similar to those of Chinese, Japanese and Malysian, but different from those of Caucacian, Indian of African. In apo(a) phenotype of Korean, the mode of single band was S3(44.3%), and the mode of double bank was S3S4(8.2%), which were similar to those of Chinese, Malysian and Indian. Order of allele frequencies of Lp(a) of Korean was Lps4, null(Lp0), Lps3, Lps2, and Lps1. Similar frequency was seen in those of Chinese, and other Asians execpt Japanese, but not in those of Caucacian and black people. Lp(a) concentration was not correlated with any other lipid profiles. Homology of study samples with Korean population was confirmed by Hardy-Weinberg equilibrium test. These results show that Korean people has higher concentration of Lp(a) in Asian, and has characteristics of apo(a) phenotype and Lp(a) allele frequences.
-
혈중 Lipoprotein ( a ) 의 농도가 인체내 혈전 생성 및 용해 인자에 미치는 영향에 관한 연구
서홍석(Hong Seog Seo),오동주(Dong Joo Oh),이은미(Eun Mi Lee),한승환(Sung Whan Han),박희남(Hui Nam Pak),임도선(Do Sun Lim),박창규(Chang Kyu Park),김영훈(Young Hoon Kim),심완주(Wan Joo Shim),노영무(Young Moo Ro),권정아(Jung Ah Kwon),이갑 대한내과학회 1996 대한내과학회지 Vol.51 No.1
N/A Objectives: Recently, lipoprotein (a) is known as an independent genetic risk factor for cardiovascular disease. Lipoprotein (a) contains a unique structure, apolipoprotein(a), that shares a partial homology with plasminogen without haboring enzymatic activity. Several in vitro studies reported that lipoprotein(a) competes with plgsminogen for their receptors showing inhibited thrombolysis and promoted thrombosis. We investigated whether evalvuated that lipoprotein(a) has same properties in vivo by determining the homeostatic relation between lipoprotein(a) concentration and several parameters of thrombosis and thrombolysis, and whether parameters of thrombosis and thrombolysis are different in atherosclerotic vascular diseases. Methods: Lipoprotein(a), fibrinogen, plasminogen, FDP-d, antithrombin-III, prothrombin time, activated partial thromboplastin time, tissue-type plasminogen activator, alpha-2 antiplasmin, plaminogen activator inhibitor-l, platelet counts, and other lipid profiles were measured and were compared each others by venous samles in 239 cases with atherosclerotic vascular disease which consisted of 146 cases of coronary heart disease, 39 cases of non-hemorrhagic cerebral infarction, and 10 cases of arteriosclerosis obliterans and in 185 cases without atherosclerotic vascular disease., Results: There was neither significant homeostatic relationship between lipoprotein(a) levels and paramets d thrombolysis, nor between lipids levels and parameters of thrombosis and thrombolysis. Serum lipoprotein(a) levels were higher in patients with myocardial infarction than in those with non- atherosclerotic vascular disease(30.0±28.2mg vs 23.8±21.4mg/dl). Among the thrombogenic and thrombolytic parameters, only tPA and FDP-d were significantly elevated in patients with atherosclerotic vascular disease. Conclusion: The findings that lipoprotien(a) was not correlated with thrombogenic and thrombolytic profiles in vivo suggests that lipoprotein(a) is not related to thrombogenicity in Korean people, al- though lipoprotein(a) is a independent genetic risk factor for carodiovascular disease.
-
-
-
고농도 Dipyridamole 심초음파를 이용한 관상동맥 질환의 진단
심완주(Wan Joo Shim),서홍석(Hong Seog Seo),안태훈(Tae Hoon Ahn),김영훈(Young Hoon Kim),오동주(Dong Joo Oh),박정의(Jeong Euy Park),노영무(Young Moo Ro) 대한내과학회 1992 대한내과학회지 Vol.43 No.5
N/A Background: Dipyridamole infusion induces myocardial ischemia in the presence of coronary artery stenosis. Regional wall motion abnormality detected by 2-dimensionai echocardiography (2DE) is a reliable sign of mycoardial ischemia. Method: Dipyridamole of 0.56mg/kg was infused over the 4 minutes and followed by 4 minutes of no infusion and then 0.28mg/kg of dipyridamole infusion during 2 minutes in 31 patients. At the baseline, full 2DE was recorded and continuous 2DE was performed during the dipyridamole infusion and 10 minutes thereafter. Blood pressure was measured every 1 minute and ECG was checked at baseline, 4 minutes 10 minutes and at the end of the study. Coronary angiography wa done in all cases within 2 minths of dipyridamole echocardiography. Result: As a criteria of myocardial ischemia, 4 parameters such as emergence of chest pain, ischemic ST change in ECG, reduction of ejection fraction and development of new abnormal regional wall motion was analysed. The sensitvity for each parameter was 52,9%, 72.2%, 77.8% and 83.3% respectively. The specificity was 100% for abnormal regional wall motion, 91.7% for reduction of ejection fraction, 76,9% for ischemic ST change and 53.8% for chest pain. No serious side effect was observed during the procedure. Comclusion: Thus we conclude high dose dipyridamole echocardiography is a safe and useful method to detect coronary artery disease especially who is unable to exercise
-
김준석(Jun Suk Kim),서홍석(Hong Seog Seo),오동주(Dong Joo Oh),임도선(Do Sun Lim) 대한약학회 1993 약학회지 Vol.37 No.1
Brovincamine is a selective cerebral vasodilator that was apparently produced via a slow calcium blockade. Brovincamine has been shown to increase ATP production and glucose and oxygen consumption in brain, improving energy metabolism. Also brovincamine inhibited platelet aggregation induced by ADP and collagen in vivo and in vitro via an increase of cAMP concentration, promoting therapeutic effects on cerebral circulatory disorders. So we investigated and represented the clinical effects and safety of brovincamine in patients with cerebral stroke. Thirty patients of cerebral stroke that was older than 2 months, who were 22 cases of cerebral infarction, 6 of cerebral embolism that originated from cerebral infarction, 6 of cerebral embolism that originated from cardiac diseases, and 2 of cerebral embolism that originated from cardiac diseases, and 2 of cerebral hemorrhage, were administered of 20 mg of oral brovincamine three times daily for 8 weeks. Improvement rates of each symptom after 8 week administration were 30.8% for subjective symptoms, 76% for psychiatric symptoms and 65.6% for neurologic symptoms. In final global improvement rates, much improvement was 10%, improvement was 23.3% slight improvement is 36.7%, and no change was 30%. So global improvement rate including slight improvement was 70%. As for side effects, there were 3 cases of mild gastrointestinal symptoms, but there were no other subjective side effects and significant fluctuation in laboratory examination. Conclusively throughout the present study, brovincamine is judged to be well tolerated and effective in patients with cerebral stroke.
-
김응주(Eung Ju Kim),서홍석(Hong Seog Seo),임성윤(Sung Yoon Lim),김미나(Mina Kim),나진오(Jin Oh Na),최철웅(Cheol Ung Choi),김진원(Jin Won Kim),임홍의(Hong Euy Lim),나승운(Seung-Woon Rha),박창규(Chang Gyu Park),오동주(Dong Joo Oh) 대한임상노인의학회 2009 대한임상노인의학회지 Vol.10 No.4
연구배경: 대동맥의 탄성은 관상동맥질환 환자에서 비정상인 것으로 알려져 있으나, 대동맥 탄성도의 지표들 중 하나인 대동맥 팽창성이 관상동맥질환과 독립적으로 연관되어 있는 지는 확실치 않다. 방법: 관상동맥 조영술을 받은 일련의 373명 중 급성관동맥 증후군, 과거 심근경색, 중등도 이상의 의미 있는 판막질환, 좌심실 구혈율 40% 미만, 심방세동, 관상동맥 성형술이나 관상동맥 우회술의 병력이 있는 사람들을 제외한 총 305명(관상동맥질환 환자군 107명, 대조군 198명)을 관찰하였다. 심장초음파를 이용하여 대동맥 판막으로부터 3 cm 원위부의 상행대동맥 직경을 측정한 후 2×(대동맥 내경의 변화)/(확장기 대동맥 내경×맥압) 공식으로 대동맥 팽창성(cm²×dyn⁻¹×10⁻⁶)을 구하였다. 결과: 수축기, 확장기 혈압과 맥박수는 양 군간 차이가 없었으나 대동맥 팽창성은 환자군이 유의하게 대조군 보다 낮았다(1.15±0.30 vs. 3.00±0.25, P<0.001). 다변량분석에서 대동맥 팽창성은 나이, 성, 고혈압, 당뇨병, 고지혈증과 흡연을 보정하고도 관상동맥질환과 유의한 상관성(P<0.001)을 보였다. 더욱이 대동맥 팽창성은 1∼3혈관질환으로 표현한 관상동맥질환의 심한 정도와 반비례하는 양상이었다(P<0.001). 결론: 대동맥 팽창성은 관상동맥질환의 독립적 위험 표지자이며 관상동맥질환의 심한 정도와 상관있는 것으로 생각된다. Background: Elastic properties of aorta have been known to be abnormal in patients with coronary artery disease (CAD). However, aortic distensibility (AD), one of the elasticity indexes, has not been ascertained whether it is independently associated with CAD. Methods: We prospectively enrolled 305 subjects (107 patients with CAD and 198 patients without it) among 373 consecutive patients undergoing coronary angiography for the assessment of suspected CAD. Patients with acute coronary syndrome, previous myocardial infarction, valvular heart disease more than mild, left ventricular ejection fraction <40%, atrial fibrillation, and history of coronary intervention or surgery were excluded. Aortic diameters were measured at a level 3 cm above the aortic valve using echocardiography. AD (cm²×dyn⁻¹×10⁻⁶) was calculated from the aortic diameters and brachial artery pressure using the formula: 2×(change in aortic diameter)/(diastolic aortic diameter ×pulse pressure). Results: Systolic, diastolic blood pressure and pulse rate were similar in both CAD and control subjects. AD was significantly lower in patients with CAD than controls (1.15±0.30 vs. 3.00±0.25, P<0.001). In multivariate analysis, AD remained significantly associated with CAD (P<0.001) after adjustment for age, gender, hypertension, diabetes, hyperlipidemia and smoking. Moreover, AD showed significant inverse relationship with the severity of CAD, expressed as one-, two-, and three-vessel disease (P<0.001). Conclusion: Our findings suggest that impaired AD is an independent risk marker for CAD, as well as significantly associated with the severity of CAD.
-
협심증에서 Diltiazem 투여에 따른 무증상 심근허혈의 변화
박창규(Chang Kyu Park),서홍석(Hong Seog Seo),오동주(Dong Joo Oh),노영무(Young Moo Ro) 대한내과학회 1989 대한내과학회지 Vol.36 No.5
N/A All of the acute and chronic ischemic syndromes can occur without chest pain, and myocrdial ischemia, regardless of chest pain, can cause congestive heart failure, arrhythmia, acute myocardial infarction or sudden edath. Also the prognosis of ischemic syndrome may be related to the total frequency of the ischemic events, both silent and symptomatic. Because silent ischemia is asymptomatic and is not preceded by an increased of heart rate and blood pressure, the most rational therapeutic approach would be to increase oxygen to the myocardium and to maintain constant therapeutic levels of drugs in the plasma. Calcium channel blockers and nitrates are optimal for these purposes. The odse of the drug needed to effectively remove silent muocardial ischemia, however, has not been well konwn. In order to evaluate the effect of diltiazem of a dose that relieves or prevents chest pain, on the modification of ischemic events, such as silent ST-segment changes in patinets with anginal pectoris, 24 hour Holter ECG recordings were obtained before and after the a dministration of a dose of diltiazem that relieves chest pain and were analyzed from 10 patients with angina pectoris, aged 44~74 years. Diltiazern reduced frequency, duration and magnitude of silent ischemia in all cases (100%), and totally removed silent ischemia in 50% of the cases and decreased the number of silent ischemic episodes from 11±11 times/24 hrs to 3 ±4 times/24 hrs (p < 0.05), and the duration from 50 ± 50 minutes/24 hrs to 14 ± 24 minutes/24 hrs (p<0.05), The degree of maximal ST depression was reduced from 2.7±1.6mm to 0.9±1.1mm (p<0.01) and the magnitude of ST depression was reduced from 85±110 mm/min to 34±89 mm/min (p=0.06). These findings suggest that oral diltiazem of a dose that relieves or prevents chest pain (90 mg-270 mg) significantly reduces silent myocardial ischemia in patients with anginal pectoris.
-
-
ScienceON연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
